Zealand Pharma Shares Slide After Boehringer Study Shows Obesity Shot’s Side Effects
RSS SUMMARY · AGGREGATED FROM TWSJ
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
Campbell’s Sales Fall on Continued Weak Demand for Snacks
TWSJ·1h ago·3 min read
Business
Once on the Brink, U.S. Steel’s Oldest Plant Is Getting a Big Renovation
TWSJ·1h ago·3 min read
Business
Honeywell Backs Full-Year Guidance Ahead of Aerospace Spinoff
TWSJ·1h ago·3 min read
Business
The Revenge of the Publicists: How Comms Execs Stormed the C-Suite
TWSJ·2h ago·3 min read
Related
On this beat
Health
Weight loss drug maker sinks 25% after new safety data spooks investors
CNBC·4h ago·3 min read
Health
Eli Lilly Shares Rise Premarket on Late-Stage Weight Loss Trial Success
TWSJ·4h ago·3 min read
Health
Life After A Spinal Injury: A Guide to Physical And Mental Recovery
AOHL·5h ago·3 min read
Health
Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch
TWSJ·7h ago·3 min read